Patent ID: 6133289
Filing Date: 2000-10-17
Classification: C07D,C08G

Abstract:
A method for treating or preventing a disorder selected form: alcoholism, anxiety, depression, obsessive compulsive disorder, panic disorder, chronic pain, obesity, senile dementia, migraine, bulimia, anorexia, social phobia, pre-menstrual syndrome, adolescent depression tichotillomania, dysthymia and substance abuse which comprises administering an effective therapeutic or prophylactic amount of paroxetine hydrochloride anhydrate Form A to a patient in need thereof, wherein paroxetine hydrochloride anhydrate Form A comprises the following characteristics: a melting point of about 123-125.degree. C.; IR bands at about 513, 538, 571, 592, 613, 665, 722, 761, 783, 806, 818, 839, 888, 906, 924, 947, 966, 982, 1006, 1034, 1068, 1091, 1134, 119,4, 1221, 1248, 1286, 1340, 1387, 1493, 1513, 1562, 1604, 3402, and 3631 cm.sup.-1 ; a DSC maximum endoderm, measured at 10.degree. C. per minute, of about 126.degree. C. in an open pan and about 121.degree. C. in a closed pan; characteristic X-ray diffractogram peaks at about 6.6, 8.0, 11.2, and 13.1 degrees 2 theta; characteristic solid state .sup.13 C-NMR spectrum peaks at about 154.3, 149.3, 141.6, and 138.5 ppm.